Welcome to our dedicated page for Liquidia news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia stock.
Liquidia Corporation develops and commercializes therapies for respiratory and vascular diseases, with a focus on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its updates center on YUTREPIA® (treprostinil) inhalation powder, the company’s PRINT® Technology-enabled approved therapy, along with L606, an investigational extended-release treprostinil formulation administered with a nebulizer, and generic Treprostinil Injection for PAH.
Recurring news includes financial results, YUTREPIA commercial uptake, clinical data presentations, pipeline studies, corporate presentations and investor conference participation. Company updates also discuss treprostinil delivery, PAH and PH-ILD treatment settings, cash generation and profitability as product sales become a larger part of Liquidia’s operating profile.
Liquidia Technologies (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company, announced that CEO Neal Fowler will present an overview at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 10:30 AM ET. The event will be accessible via a live audio webcast, available on the company’s website and archived for 90 days. Liquidia focuses on developing novel products using its proprietary PRINT® technology, aiming to enhance therapy safety and efficacy. Notable product candidates include LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain.
Liquidia Technologies (LQDA) announced the appointment of Dr. Tushar Shah as Chief Medical Officer. Dr. Shah brings 27 years of experience in pharmaceutical research, overseeing clinical development activities. His previous roles include Head of Global Specialty Clinical Development at Teva Pharmaceuticals. This leadership change is expected to enhance Liquidia's capabilities, particularly as it advances LIQ861 (pending NDA review) and LIQ865 (currently in clinical development), utilizing Liquidia's proprietary PRINT technology.
Liquidia Technologies, Inc. (LQDA) will announce its first quarter 2020 financial results on May 11, 2020, at 4:30 p.m. ET. The company plans to host a webcast and conference call to discuss these results and provide a corporate update.
Liquidia is focused on developing novel biopharmaceutical products using its proprietary PRINT® technology, with two primary candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain treatment.
Summary not available.